JP2016539129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539129A5 JP2016539129A5 JP2016533609A JP2016533609A JP2016539129A5 JP 2016539129 A5 JP2016539129 A5 JP 2016539129A5 JP 2016533609 A JP2016533609 A JP 2016533609A JP 2016533609 A JP2016533609 A JP 2016533609A JP 2016539129 A5 JP2016539129 A5 JP 2016539129A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- cell
- melanoma
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 claims description 135
- 239000000203 mixture Substances 0.000 claims description 58
- 206010025650 Malignant melanoma Diseases 0.000 claims description 56
- 201000001441 melanoma Diseases 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 50
- -1 silendide Chemical compound 0.000 claims description 20
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims description 16
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 230000002496 gastric Effects 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 200000000023 metastatic cancer Diseases 0.000 claims description 8
- 150000003384 small molecules Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 206010024324 Leukaemias Diseases 0.000 claims description 6
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010025310 Other lymphomas Diseases 0.000 claims description 6
- 201000005216 brain cancer Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 4
- 210000003445 Biliary Tract Anatomy 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 208000002458 Carcinoid Tumor Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
- 210000000232 Gallbladder Anatomy 0.000 claims description 4
- 206010017758 Gastric cancer Diseases 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 108010091266 Gemtuzumab Proteins 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001156 Mitoxantrone Drugs 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- 206010029488 Nodular melanoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- YGKUEOZJFIXDGI-UHFFFAOYSA-N Pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 206010038038 Rectal cancer Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 108090001123 antibodies Proteins 0.000 claims description 4
- 102000004965 antibodies Human genes 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000011231 colorectal cancer Diseases 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 230000001079 digestive Effects 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 230000003352 fibrogenic Effects 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- 229960000578 gemtuzumab Drugs 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims description 4
- 201000003731 mucosal melanoma Diseases 0.000 claims description 4
- 201000009251 multiple myeloma Diseases 0.000 claims description 4
- 201000000032 nodular malignant melanoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000002314 small intestine cancer Diseases 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 230000002588 toxic Effects 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 210000004881 tumor cells Anatomy 0.000 claims description 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims description 2
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 claims description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims description 2
- 208000004064 Acoustic Neuroma Diseases 0.000 claims description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 229950009084 Adecatumumab Drugs 0.000 claims description 2
- 208000009956 Adenocarcinoma Diseases 0.000 claims description 2
- 108010090838 Alemtuzumab Proteins 0.000 claims description 2
- 229950001537 Amatuximab Drugs 0.000 claims description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001220 Amsacrine Drugs 0.000 claims description 2
- 229950003145 Apolizumab Drugs 0.000 claims description 2
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010005144 Bevacizumab Proteins 0.000 claims description 2
- 229960001561 Bleomycin Drugs 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 108010013795 Brentuximab Vedotin Proteins 0.000 claims description 2
- 229960000455 Brentuximab vedotin Drugs 0.000 claims description 2
- 229960004562 Carboplatin Drugs 0.000 claims description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 2
- 229950000771 Carlumab Drugs 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 2
- 108010022830 Cetuximab Proteins 0.000 claims description 2
- 229960004630 Chlorambucil Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 108010084740 Daclizumab Proteins 0.000 claims description 2
- 229960000975 Daunorubicin Drugs 0.000 claims description 2
- 229950008962 Detumomab Drugs 0.000 claims description 2
- 229940120124 Dichloroacetate Drugs 0.000 claims description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004679 Doxorubicin Drugs 0.000 claims description 2
- 108010070635 Edrecolomab Proteins 0.000 claims description 2
- 229950009760 Epratuzumab Drugs 0.000 claims description 2
- 229960001433 Erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 Etoposide Drugs 0.000 claims description 2
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 claims description 2
- 229950009929 Farletuzumab Drugs 0.000 claims description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N Fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003980 Galantamine Drugs 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 2
- 108010027059 Inotuzumab Ozogamicin Proteins 0.000 claims description 2
- 229950004101 Inotuzumab ozogamicin Drugs 0.000 claims description 2
- 229950001014 Intetumumab Drugs 0.000 claims description 2
- 108010089187 Ipilimumab Proteins 0.000 claims description 2
- 229950010939 Iratumumab Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- IQVRBWUUXZMOPW-PKNBQFBNSA-N Istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 claims description 2
- 229950009028 Istradefylline Drugs 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 206010023774 Large cell lung cancer Diseases 0.000 claims description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 2
- 229950002884 Lexatumumab Drugs 0.000 claims description 2
- 229950002950 Lintuzumab Drugs 0.000 claims description 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 206010027191 Meningioma Diseases 0.000 claims description 2
- 206010028549 Myeloid leukaemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 2
- 229960002450 Ofatumumab Drugs 0.000 claims description 2
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims description 2
- 229950007283 Oregovomab Drugs 0.000 claims description 2
- 229950011098 PENDETIDE Drugs 0.000 claims description 2
- 108010061219 Panitumumab Proteins 0.000 claims description 2
- RKEWSXXUOLRFBX-UHFFFAOYSA-N Pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 229950003764 Pridopidine Drugs 0.000 claims description 2
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 claims description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 2
- NEMGRZFTLSKBAP-LBPRGKRZSA-N Safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims description 2
- 229950002652 Safinamide Drugs 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 229950003647 Semaxanib Drugs 0.000 claims description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 210000002784 Stomach Anatomy 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 108091008149 TGN-1412 Proteins 0.000 claims description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 2
- 229960001603 Tamoxifen Drugs 0.000 claims description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
- 229960001278 Teniposide Drugs 0.000 claims description 2
- 229960005333 Tetrabenazine Drugs 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- 229960001196 Thiotepa Drugs 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 108010010691 Trastuzumab Proteins 0.000 claims description 2
- 229950007217 Tremelimumab Drugs 0.000 claims description 2
- 229960003048 Vinblastine Drugs 0.000 claims description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 241000863480 Vinca Species 0.000 claims description 2
- 229960004528 Vincristine Drugs 0.000 claims description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 101710026163 acu-8 Proteins 0.000 claims description 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 2
- 108091003858 adecatumumab Proteins 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 229930013930 alkaloids Natural products 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 108091020210 amatuximab Proteins 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 2
- 108010062611 apolizumab Proteins 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960002938 bexarotene Drugs 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 108091020428 carlumab Proteins 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical compound [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 229960001776 edrecolomab Drugs 0.000 claims description 2
- 108010007604 epratuzumab Proteins 0.000 claims description 2
- 229960000752 etoposide phosphate Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 108010087285 farletuzumab Proteins 0.000 claims description 2
- 229960002435 fasudil Drugs 0.000 claims description 2
- 229960000556 fingolimod Drugs 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 229960003776 glatiramer acetate Drugs 0.000 claims description 2
- 201000010915 glioblastoma multiforme Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 108010009550 intetumumab Proteins 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 108010093819 iratumumab Proteins 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229960004427 isradipine Drugs 0.000 claims description 2
- 108010046731 lexatumumab Proteins 0.000 claims description 2
- 108010018575 lintuzumab Proteins 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 230000000683 nonmetastatic Effects 0.000 claims description 2
- 108010052070 ofatumumab Proteins 0.000 claims description 2
- 108010060422 oregovomab Proteins 0.000 claims description 2
- 210000000056 organs Anatomy 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 108010092042 pemtumomab Proteins 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 claims description 2
- 229960003300 pimavanserin Drugs 0.000 claims description 2
- 201000005746 pituitary adenoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 229960000235 temsirolimus Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 108010072993 tremelimumab Proteins 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims 2
- 229950007699 Mogamulizumab Drugs 0.000 claims 1
- 229950010203 Nimotuzumab Drugs 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 229950008684 Sibrotuzumab Drugs 0.000 claims 1
- 229950000815 Veltuzumab Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 108010007997 mogamulizumab Proteins 0.000 claims 1
- 108010043585 nimotuzumab Proteins 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 108010042024 pertuzumab Proteins 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 230000002285 radioactive Effects 0.000 claims 1
- 108010026911 ramucirumab Proteins 0.000 claims 1
- 229960002633 ramucirumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 108010043794 sibrotuzumab Proteins 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 108010063727 veltuzumab Proteins 0.000 claims 1
- 229950001869 Mapatumumab Drugs 0.000 description 1
- 229950008001 Matuzumab Drugs 0.000 description 1
- 229950008516 Olaratumab Drugs 0.000 description 1
- 229950000846 Onartuzumab Drugs 0.000 description 1
- 229950010966 Patritumab Drugs 0.000 description 1
- 229950009904 Pritumumab Drugs 0.000 description 1
- 229950010265 Tabalumab Drugs 0.000 description 1
- 229950001289 Tenatumomab Drugs 0.000 description 1
- 229950010259 Teprotumumab Drugs 0.000 description 1
- 108010021856 mapatumumab Proteins 0.000 description 1
- 108010029633 matuzumab Proteins 0.000 description 1
- 108010049284 olaratumab Proteins 0.000 description 1
- 108010092946 onartuzumab Proteins 0.000 description 1
- 108091005397 patritumab Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010056973 siltuximab Proteins 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 108010029352 tabalumab Proteins 0.000 description 1
- 108091015329 teprotumumab Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906817P | 2013-11-20 | 2013-11-20 | |
| US61/906,817 | 2013-11-20 | ||
| PCT/US2014/066543 WO2015077411A1 (en) | 2013-11-20 | 2014-11-20 | Curcuphenol compounds for increasing mhc-i expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132434A Division JP2019196380A (ja) | 2013-11-20 | 2019-07-18 | Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539129A JP2016539129A (ja) | 2016-12-15 |
| JP2016539129A5 true JP2016539129A5 (zh) | 2017-12-28 |
| JP6560215B2 JP6560215B2 (ja) | 2019-08-14 |
Family
ID=52117996
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533609A Active JP6560215B2 (ja) | 2013-11-20 | 2014-11-20 | Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物 |
| JP2019132434A Withdrawn JP2019196380A (ja) | 2013-11-20 | 2019-07-18 | Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物 |
| JP2021064761A Active JP7071570B2 (ja) | 2013-11-20 | 2021-04-06 | Ｍｈｃ－ｉの発現を増加させるためのクルクフェノール化合物 |
| JP2022076869A Pending JP2022093724A (ja) | 2013-11-20 | 2022-05-09 | Ｍｈｃ－ｉの発現を増加させるためのクルクフェノール化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132434A Withdrawn JP2019196380A (ja) | 2013-11-20 | 2019-07-18 | Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物 |
| JP2021064761A Active JP7071570B2 (ja) | 2013-11-20 | 2021-04-06 | Ｍｈｃ－ｉの発現を増加させるためのクルクフェノール化合物 |
| JP2022076869A Pending JP2022093724A (ja) | 2013-11-20 | 2022-05-09 | Ｍｈｃ－ｉの発現を増加させるためのクルクフェノール化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20150147314A1 (zh) |
| EP (2) | EP3071192B1 (zh) |
| JP (4) | JP6560215B2 (zh) |
| CN (1) | CN106456572A (zh) |
| CA (1) | CA2930156C (zh) |
| DK (1) | DK3071192T3 (zh) |
| ES (1) | ES2775577T3 (zh) |
| HU (1) | HUE049301T2 (zh) |
| PL (1) | PL3071192T3 (zh) |
| WO (1) | WO2015077411A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3071192T3 (pl) | 2013-11-20 | 2020-06-29 | Cava Healthcare Inc. | Związek kurkufenol do zastosowania w leczeniu nowotworu |
| WO2017015615A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| KR20220004952A (ko) | 2019-01-31 | 2022-01-12 | 카바 헬스케어 아이엔씨. | Mhc-i 발현 증가 및 히스톤 디아세틸라제 활성 조절을 위한 화합물 |
| TW202214245A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 雙非癌藥物用於製備治療癌症之醫藥組合物的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6261939A (ja) * | 1985-09-10 | 1987-03-18 | Yamanouchi Pharmaceut Co Ltd | クルクフエノ−ル誘導体及びこれを含有する医薬 |
| KR100439425B1 (ko) * | 2001-03-22 | 2004-07-05 | (주)바이오케어 | 잔토리졸을 포함하는 조성물 및 그 용도 |
| JP2007521260A (ja) * | 2003-06-24 | 2007-08-02 | バイオケア カンパニ−リミテッド | 抗癌剤で誘発される毒性の抑制剤及びこれを含有する抗癌剤組成物 |
| CA2688570A1 (en) * | 2007-05-31 | 2008-12-04 | F.P.L. Pharma Inc. | Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof |
| PL3071192T3 (pl) | 2013-11-20 | 2020-06-29 | Cava Healthcare Inc. | Związek kurkufenol do zastosowania w leczeniu nowotworu |
-
2014
- 2014-11-20 PL PL14815145T patent/PL3071192T3/pl unknown
- 2014-11-20 HU HUE14815145A patent/HUE049301T2/hu unknown
- 2014-11-20 WO PCT/US2014/066543 patent/WO2015077411A1/en active Application Filing
- 2014-11-20 ES ES14815145T patent/ES2775577T3/es active Active
- 2014-11-20 DK DK14815145.9T patent/DK3071192T3/da active
- 2014-11-20 CA CA2930156A patent/CA2930156C/en active Active
- 2014-11-20 EP EP14815145.9A patent/EP3071192B1/en active Active
- 2014-11-20 US US14/548,726 patent/US20150147314A1/en not_active Abandoned
- 2014-11-20 JP JP2016533609A patent/JP6560215B2/ja active Active
- 2014-11-20 EP EP19216024.0A patent/EP3639815A1/en active Pending
- 2014-11-20 CN CN201480072728.3A patent/CN106456572A/zh active Pending
-
2017
- 2017-01-25 US US15/415,291 patent/US10751296B2/en active Active
-
2019
- 2019-07-18 JP JP2019132434A patent/JP2019196380A/ja not_active Withdrawn
-
2020
- 2020-08-20 US US16/998,072 patent/US11197832B2/en active Active
-
2021
- 2021-04-06 JP JP2021064761A patent/JP7071570B2/ja active Active
- 2021-11-08 US US17/521,674 patent/US12011421B2/en active Active
-
2022
- 2022-05-09 JP JP2022076869A patent/JP2022093724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11433143B2 (en) | Nano-enabled immunotherapy in cancer | |
| AU2018269742A1 (en) | Nano-enabled immunotherapy in cancer | |
| JP2016539129A5 (zh) | ||
| US20230241000A1 (en) | Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic | |
| US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| US12011421B2 (en) | Curcuphenol compounds for increasing MHC-I expression | |
| EP4011391A1 (en) | Biomarker for accessing efficacy of immune checkpoint inhibitor | |
| WO2021206160A1 (ja) | 抗体薬物複合体 | |
| JP2019069990A (ja) | 癌を処置するためのセファロスポリンの新規誘導体 | |
| TWI744730B (zh) | 用於遞送抗癌劑之立體複合物 | |
| US20220249682A1 (en) | Polymeric drug delivery conjugates and methods of making and using thereof | |
| WO2021205631A1 (ja) | Ｓｔｉｎｇ作動化合物 | |
| JP2020132638A5 (zh) | ||
| WO2021206158A1 (ja) | がん治療方法 | |
| JPWO2019244979A1 (ja) | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 | |
| US12029792B2 (en) | Stereocomplexes for the delivery of anti-cancer agents | |
| CA3210086A1 (en) | Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer | |
| WO2023196984A2 (en) | Multifunctional nanoparticles and uses in managing cancer and cardiovascular diseases | |
| WO2023081809A1 (en) | Trans-cyclooctene-modified bispecific antibodies | |
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| KR20230041581A (ko) | 세포 식균 작용을 증가시키는 방법 | |
| JP2021167308A (ja) | Ｓｔｉｎｇ作動化合物 | |
| JPWO2020117742A5 (zh) |